GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Quantum BioPharma Ltd (STU:0K91) » Definitions » EV-to-EBIT

Quantum BioPharma (STU:0K91) EV-to-EBIT : 0.30 (As of May. 13, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Quantum BioPharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Quantum BioPharma's Enterprise Value is €-4.20 Mil. Quantum BioPharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-13.82 Mil. Therefore, Quantum BioPharma's EV-to-EBIT for today is 0.30.

The historical rank and industry rank for Quantum BioPharma's EV-to-EBIT or its related term are showing as below:

STU:0K91' s EV-to-EBIT Range Over the Past 10 Years
Min: -237.84   Med: -0.16   Max: 45439.45
Current: 0.32

During the past 10 years, the highest EV-to-EBIT of Quantum BioPharma was 45439.45. The lowest was -237.84. And the median was -0.16.

STU:0K91's EV-to-EBIT is ranked better than
97.21% of 682 companies
in the Drug Manufacturers industry
Industry Median: 16.34 vs STU:0K91: 0.32

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Quantum BioPharma's Enterprise Value for the quarter that ended in Dec. 2024 was €1.66 Mil. Quantum BioPharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was €-13.82 Mil. Quantum BioPharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -832.27%.


Quantum BioPharma EV-to-EBIT Historical Data

The historical data trend for Quantum BioPharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantum BioPharma EV-to-EBIT Chart

Quantum BioPharma Annual Data
Trend Aug15 Aug16 Aug17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.45 -0.20 -0.49 -1.74 -0.07

Quantum BioPharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.74 -2.24 -0.42 - -0.07

Competitive Comparison of Quantum BioPharma's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Quantum BioPharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quantum BioPharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Quantum BioPharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Quantum BioPharma's EV-to-EBIT falls into.


;
;

Quantum BioPharma EV-to-EBIT Calculation

Quantum BioPharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-4.199/-13.824
=0.30

Quantum BioPharma's current Enterprise Value is €-4.20 Mil.
Quantum BioPharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantum BioPharma  (STU:0K91) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Quantum BioPharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=-13.824/1.661
=-832.27 %

Quantum BioPharma's Enterprise Value for the quarter that ended in Dec. 2024 was €1.66 Mil.
Quantum BioPharma's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-13.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quantum BioPharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Quantum BioPharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Quantum BioPharma Business Description

Traded in Other Exchanges
Address
55 University Avenue, Suite 1003, Toronto, ON, CAN, M5J 2H7
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.

Quantum BioPharma Headlines

No Headlines